Aardvark Therapeutics (AARDV) Forms Ardia Subsidiary to Advance Dermatology Pipeline

Aardvark Therapeutics (NASDAQ: AARDV) announced the formation of Ardia, a wholly-owned subsidiary, to focus on the development and commercialization of its dermatology pipeline. The move is expected to accelerate trials and bring novel treatments for skin conditions to market. Key assets include ARX-888, a first-in-class small-molecule inhibitor in Phase III trials for atopic dermatitis, and ARX-889, in Phase II for psoriasis. The subsidiary will leverage Aardvark's internal manufacturing and salesforce to expedite regulatory approvals and market entry. Financial terms were not disclosed, but the transaction is expected to strengthen the company's position in the dermatology segment.